Articles

Podcasts

Videos

Clinical

The Centers for Disease Control and Prevention's (CDC) VISION Network of health care systems provided data for test-negative design analysis of vaccine effectiveness in preventing COVID-19 acute admissions.

Quantifying Vaccine Effectiveness in Preventing Severe COVID-19

After voting against recommendation of a booster dose for people 16 years and older, the committee created a new question to vote on an EUA for a booster dose for people 65 years and older and those at high risk of COVID-19. They voted 18-0 in favor.

FDA Committee Votes to Recommend EUA of COVID-19 Booster Dose in Older, High-Risk People

The VRBPAC voted 16-2 on Friday afternoon on the question they were presented.

FDA VRBPAC Votes Against Recommending Approval of Booster Dose of Pfizer-BioNTech COVID-19 Vaccine

A new study addressed the clinical outcomes in young adults who were hospitalized with COVID-19 across the United States.

Understanding Young Adult Hospitalizations in COVID-19

A Food and Drug Administration (FDA) committee will discuss this topic as it pertains to the potential approval of a third dose of the Pfizer-BioNTech COVID-19 vaccine. The results of this meeting could have ramifications for the Biden Administration’s COVID-19 health policy.

FDA Meeting Today to Discuss Booster Doses

The emergency authorization granted to combination bamlanivimab and etesevimab is the second indicated in this last year.

FDA Authorizes Monoclonal Antibodies for Post-Exposure COVID-19 Prevention

Based on recent studies, the company sees benefits in administering booster doses.  

Moderna COVID-19 Vaccine Remains Effective, Shows Waning Immunity Several Months After

Recent data shows that all three COVID-19 vaccines being administered in the United States are showing high rates of vaccine effectiveness (VE). 

Vaccines Remain Effective Against Delta 

Though efficacy waned over months, protection from symptomatic and severe COVID-19 remained significant, with no new adverse event risks observed.

Pfizer COVID-19 Vaccine Shows Continued Efficacy, Safety at 6 Months

In a recent speech, Pfizer’s CFO says it might be a matter of weeks for submitting an application for children 6 months to 5 years old.

CORONAVIRUS